← Patent-cliff monitor Loss of exclusivity May 2031 latest FDA-listed patent expiry
Company ASTRAZENECA AB
Drug detail Brand name XIGDUO XR Active ingredient DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE Strength 5MG;500MG Dosage form TABLET, EXTENDED RELEASE Route ORAL Modality Small molecule FDA approval October 2014 Marketing status RX
Listed patents Patent Expires Type 9616028*PED May 2031 — 8685934*PED November 2030 — 9616028 November 2030 product 7919598*PED June 2030 — 8685934 May 2030 use U-1522 7919598 December 2029 substance 8501698*PED December 2027 — 8501698 June 2027 product 6515117*PED April 2026 — 6515117 October 2025 substance, product
Regulatory exclusivity Code Expires PED December 2027 NPP June 2027
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.